Atypical meningoma: current management dilemmas and prospective clinical trials

Journal of Neuro-Oncology

Volumn 121, Issue 1, 2015, Pages 1-7

  Jenkinson, Michael D ^a,b   Weber, Damien C ^c,d   Haylock, Brian J ^e   Mallucci, Conor L ^b,f   Zakaria, Rasheed ^a   Javadpour, Mohsen ^g  

^a THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c PAUL SCHERRER INSTITUTE   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^f ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^g BEAUMONT HOSPITAL   (Ireland)

Author keywords

Atypical meningioma; Radiotherapy; Surgery; Trials

Indexed keywords

ADJUVANT THERAPY; AGE; ATYPICAL MENINGOMA; CANCER SURGERY; CLINICAL TRIAL (TOPIC); EXTERNAL BEAM RADIOTHERAPY; HISTOPATHOLOGY; HUMAN; MENINGIOMA; MENTAL PERFORMANCE; MITOSIS; NEUROSURGERY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; TUMOR INVASION; TUMOR LOCALIZATION; TUMOR RECURRENCE; MENINGEAL NEOPLASMS; PATHOLOGY;

CLINICAL TRIALS AS TOPIC; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; RADIOTHERAPY, ADJUVANT;

EID: 84921935896     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1620-1     Document Type: Review

References (34)

1. Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neuro-oncol 99(3):307–314. doi:10.1007/s11060-010-0386-3
2. Louis DN, Ohgaki H, Wiestler OD et al (2007) WHO classification of tumours of the central nervous system. IARC Press, Lyon
3. Aghi MK, Carter BS, Cosgrove GR, Ojemann RG, Amin-Hanjani S, Martuza RL, Curry WT Jr, Barker FG II (2009) Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 64(1):56–60. doi:10.1227/01.NEU.0000330399.55586.63 (discussion 60)
4. Jo K, Park HJ, Nam DH, Lee JI, Kong DS, Park K, Kim JH (2010) Treatment of atypical meningioma. J.clin neurosci: off j Neurosurg Soc Australas 17(11):1362–1366. doi:10.1016/j.jocn.2010.03.036
5. Park HJ, Kang HC, Kim IH, Park SH, Kim DG, Park CK, Paek SH, Jung HW (2013) The role of adjuvant radiotherapy in atypical meningioma. J Neurooncol 115(2):241–247. doi:10.1007/s11060-013-1219-y
6. Rogers L, Gilbert M, Vogelbaum MA (2010) Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol 99(3):393–405. doi:10.1007/s11060-010-0343-1
7. Adeberg S, Hartmann C, Welzel T, Rieken S, Habermehl D, von Deimling A, Debus J, Combs SE (2012) Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas–clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. Int J Radiat Oncol Biol Phys 83(3):859–864. doi:10.1016/j.ijrobp.2011.08.010
8. Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon
9. Pearson BE, Markert JM, Fisher WS, Guthrie BL, Fiveash JB, Palmer CA, Riley K (2008) Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus 24(5):E3. doi:10.3171/FOC/2008/24/5/E3
10. Backer-Grondahl T, Moen BH, Torp SH (2012) The histopathological spectrum of human meningiomas. Int j clin exp pathol 5(3):231–242
11. Willis J, Smith C, Ironside JW, Erridge S, Whittle IR, Everington D (2005) The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol 31(2):141–149. doi:10.1111/j.1365-2990.2004.00621.x
12. Perry A (2006) Meningiomas. Russell and Rubinstein’s pathology of tumors of the nervous system, 7th edn. Hodder Arnold, London
13. Hakyemez B, Yildirim N, Gokalp G, Erdogan C, Parlak M (2006) The contribution of diffusion-weighted MR imaging to distinguishing typical from atypical meningiomas. Neuroradiology 48(8):513–520. doi:10.1007/s00234-006-0094-z
14. Cabada T, Caballero MC, Insausti I, Alvarez de Eulate N, Bacaicoa C, Zazpe I, Tunon T (2009) The role of diffusion-weighted imaging in the evaluation of meningiomas: radio-pathologic correlation. Radiologia 51(4):411–419. doi:10.1016/j.rx.2009.01.017
15. Kane AJ, Sughrue ME, Rutkowski MJ, Shangari G, Fang S, McDermott MW, Berger MS, Parsa AT (2011) Anatomic location is a risk factor for atypical and malignant meningiomas. Cancer 117(6):1272–1278. doi:10.1002/cncr.25591
16. Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20(1):22–39
17. Sughrue ME, Kane AJ, Shangari G, Rutkowski MJ, McDermott MW, Berger MS, Parsa AT (2010) The relevance of Simpson grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. J Neurosurg 113(5):1029–1035. doi:10.3171/2010.3.JNS091971
18. Komotar RJ, Iorgulescu JB, Raper DM, Holland EC, Beal K, Bilsky MH, Brennan CW, Tabar V, Sherman JH, Yamada Y, Gutin PH (2012) The role of radiotherapy following gross-total resection of atypical meningiomas. J Neurosurg 117(4):679–686. doi:10.3171/2012.7.JNS112113
19. Mair R, Morris K, Scott I, Carroll TA (2011) Radiotherapy for atypical meningiomas. J Neurosurg 115(4):811–819. doi:10.3171/2011.5.JNS11112
20. Vogelbaum MA, Leland Rogers C, Linskey MA, Mehta MP (2010) Opportunities for clinical research in meningioma. J Neuro-oncol 99(3):417–422. doi:10.1007/s11060-010-0375-6
21. Pollock BE (2013) Defining the best management for patients with intracranial World Health Organization grade II meningiomas. World neurosurg. doi:10.1016/j.wneu.2013.08.051
22. Austin H, Hill HA, Flanders WD, Greenberg RS (1994) Limitations in the application of case-control methodology. Epidemiol Rev 16(1):65–76
23. Kaur G, Sayegh ET, Larson A, Bloch O, Madden M, Sun MZ, Barani IJ, James CD, Parsa AT (2014) Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neurooncol 16(5):628–636. doi:10.1093/neuonc/nou025
24. Marcus HJ, Price SJ, Wilby M, Santarius T, Kirollos RW (2008) Radiotherapy as an adjuvant in the management of intracranial meningiomas: are we practising evidence-based medicine? Br J Neurosurg 22(4):520–528. doi:10.1080/02688690802308687
25. Simon M, Bostrom J, Koch P, Schramm J (2006) Interinstitutional variance of postoperative radiotherapy and follow up for meningiomas in Germany: impact of changes of the WHO classification. J Neurol Neurosurg Psychiatry 77(6):767–773. doi:10.1136/jnnp.2005.077974
26. Weber DC, Lovblad KO, Rogers L (2010) New pathology classification, imagery techniques and prospective trials for meningiomas: the future looks bright. Curr Opin Neurol 23(6):563–570. doi:10.1097/WCO.0b013e328340441e
27. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC (1999) “Malignancy” in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 85(9):2046–2056
28. Donovan J, Mills N, Smith M, Brindle L, Jacoby A, Peters T, Frankel S, Neal D, Hamdy F (2002) Quality improvement report: improving design and conduct of randomised trials by embedding them in qualitative research: protect (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. BMJ 325(7367):766–770
29. Mills N, Donovan JL, Wade J, Hamdy FC, Neal DE, Lane JA (2011) Exploring treatment preferences facilitated recruitment to randomized controlled trials. J Clin Epidemiol 64(10):1127–1136. doi:10.1016/j.jclinepi.2010.12.017
30. O’Cathain A, Thomas KJ, Drabble SJ, Rudolph A, Hewison J (2013) What can qualitative research do for randomised controlled trials? A systematic mapping review. BMJ open. doi:10.1136/bmjopen-2013-002889
31. Preusser M, Spiegl-Kreinecker S, Lotsch D, Wohrer A, Schmook M, Dieckmann K, Saringer W, Marosi C, Berger W (2012) Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer 118(20):5038–5049. doi:10.1002/cncr.27460
32. Vranic A, Peyre M, Kalamarides M (2012) New insights into meningioma: from genetics to trials. Curr Opin Oncol 24(6):660–665. doi:10.1097/CCO.0b013e3283571a06
33. Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen P, Ducar MD, Raza A, Sunkavalli A, Macconaill LE, Stemmer-Rachamimov AO, Louis DN, Hahn WC, Dunn IF, Beroukhim R (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45(3):285–289. doi:10.1038/ng.2526
34. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avsar T, Li J, Murray PB, Henegariu O, Yilmaz S, Gunel JM, Carrion-Grant G, Yilmaz B, Grady C, Tanrikulu B, Bakircioglu M, Kaymakcalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilguvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kilic T, Lifton RP, Noonan JP, Yasuno K, Gunel M (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339(6123):1077–1080. doi:10.1126/science.1233009